Multiple Sclerosis Therapies
Multiple Sclerosis Market

Multiple Sclerosis 


Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In multiple sclerosis, the body’s own immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.


Multiple Sclerosis Epidemiology Segmentation in the 7MM


  • Prevalence of Multiple Sclerosis based on Gender
  • Total Prevalent Cases of Multiple Sclerosis
  • Phenotype-specific prevalent cases of Multiple Sclerosis
  • Prevalence of Multiple Sclerosis based on Age
  • Expanded Disability Status Scale


Multiple Sclerosis Epidemiological Insights Observed in the 7MM (2020)


  • The total prevalent cases of Multiple Sclerosis in the 7MM were found to be 1.2 million in the year 2020.


Multiple Sclerosis Market Insight


The market size of Multiple Sclerosis in the 7MM was found to be almost USD 22,381 million in 2020.  


Multiple Sclerosis Market Drivers


  • Increasing population with Multiple Sclerosis
  • Extensively approved therapies
  • Wide range of R&D pipelines
  • Increasing awareness


Multiple Sclerosis Market Barriers


  • High cost of drugs
  • High incidence of adverse events
  • Patent expiration


Multiple Sclerosis Emerging Therapies


The emerging drugs in the Multiple Sclerosis market are

  • NeuroVax
  • CNM-Au8
  • Tolebrutinib
  • Evobrutinib/M2951
  • Ublituximab, and others


Multiple Sclerosis Key Players 


The key players working in the Multiple Sclerosis market are


  • Immune Response BioPharma, Inc
  • Clene Nanomedicine
  • Sanofi
  • Merck Healthcare KGaA
  • TG Therapeutics, Inc., and several others